Objectives: Thyroid carcinoma (TC) represents a malignant neoplasm affecting the thyroid. Current treatment strategies include the removal of part of the thyroid; however, this approach is associated with a significant risk of developing hypothyroidism.
| INTRODUC TI ON
As the most common malignancy of the endocrine organs, thyroid carcinoma (TC) often manifests itself as a tumour afflicting the thyroid epithelium. Studies have highlighted a rapid increase in TC incidence worldwide (>5% annually) with reports indicating that women tend to be much more susceptible than their male counterparts. 1, 2 There are two differentiated subtypes of TC malignancies namely, follicular thyroid carcinoma and papillary thyroid carcinoma, both of which generally require extended periods to heal or to progress. 3 Generally speaking, patients suffer from TC often undergo surgical treatment, including total thyroidectomy, and radioactive iodine both of which are widely considered to be a standard treatment option in clinical practice. That being said, both total thyroidectomy as well as radioactive iodine procedures can result in regional recurrence, which may lead to a reduction in life quality. 4 Thus, new progressive therapies are required in order to more effectively target thyroid tumours. LncRNAs represent RNAs longer than 200 nucleotides, which have been linked to various biological processes, including that of nuclear import and RNA transcription.
Our ever-expanding knowledge of long non-coding RNAs (lncRNAs)
represents an opportunity to identify new therapeutic targets.
The altered expression of lncRNAs has been shown to be a critical process in thyroid carcinogenesis and has been linked to with patients having more adverse prognoses. 5 The functions of lncRNAs have been documented in relation to their involvement in gene regulation at a post-transcriptional level. 6 For example, the lncRNA NAMA has been revealed as a downstream target gene of the mitogen-activated protein kinase pathway with reports linking it to cellular-growth arrest in papillary thyroid carcinoma. 7 Serine/ threonine-protein kinase 4 (STK4), also referred to as mammalian sterile 20-like kinase-1 and Krs-2, is a 56-60-kDa protein that has been shown to be down-regulated in various cancers, including that of prostate cancer and hepatocellular carcinoma. 8, 9 In addition, existing literature has suggested that DNA hypermethylation and post-translational modification can mediate the loss of STK4 activity. 10 Ready et al concluded that the dysregulation of STK4 is linked to carcinogenesis associated with poor outcomes in addition to implicating the Hippo signalling pathway in this process. 11 The
Hippo signalling pathway, comprised of mammalian STE20-like protein kinase 1 and 2 (MST1/2), large tumour suppressor kinase 1/2 (LAST1/2) and its downstream transcription co-activator, Yesassociated protein (YAP), have been implicated in the regulation of tumour suppression concerning tissue repair and regeneration. 12 Based on the exploration of the aforementioned literature, we asserted the hypothesis that lncRNA TNRC6C-AS1 could potentially work in tandem with STK4 and the Hippo signalling pathway in TC cells, whereby tumour progression can be regulated.
| MATERIAL S AND ME THODS

| Ethics statement
The study was conducted with the approval of the Medical Ethics
Committee of Suqian First Hospital and Huai'an Hospital Affiliated to Xuzhou Medical College and Huai'an Second People's Hospital.
All animal experiments were performed in strict accordance with the approval of the Animal Protection and Use Committee. All participants signed written informed consents.
| Screening of differentially expressed genes in TC
Differentially expressed genes (DEGs) in TC were downloaded from the TCGA (http://cancergenome.nih.gov/) database, with R software employed for statistical analysis. Differential analysis was conducted for the transcriptome profiling data with package edgeR of R. 13 Falsepositive discovery (FDR) correction was performed on P-values with the multitest package. FDR value of <0.05 and |log2 (fold change)| value of >2 were used as the threshold when screening out DEGs.
| Study subjects
A total of 156 specimens (TC and adjacent normal tissues) were ob- 14 all cases in the current study were confirmed by means of morphological observation, while all diagnoses were made 
TA B L E 1 Primer sequences for RT-qPCR
| Immunohistochemistry
The sliced tissue samples were incubated at 4°C overnight with a rabbit anti-human STK4 primary antibody (ab97399, 1:300; Abcam, Cambridge, MA, USA). The slices were then washed three times with Carlsbad, CA, USA) was applied for DNA methylation, followed by PCR amplification. The primers for STK4 MSP-M and STK4 MSP-U were synthesized by Sangon Biotech (Shanghai, China), as illustrated in Table 1 . The reaction conditions employed were as follows: pre-denaturation at 95°C for 10 minute, and 35 cycles of denaturation at 94°C for 1 minute, annealing at 60°C for 50 second and extension at 72°C for 10 minute. PCR products were resolved using a 20 g/L agarose.
The results obtained were then observed using an automatic analysis system of electrophoresis gel imaging. Due to the fact that the methylated primers could amplify products while the unmethylated primers could not amplify products, the primers were identified as fully methylated, fully unmethylated and partly unmethylated. 17 The aforementioned method was applicable in an identical fashion to the detection among the cells. Each experiment was repeated three times.
| Reverse transcription quantitative PCR
Total RNA was extracted from both the TC and adjacent normal tissues using a TRIZOL kit (15596-018; Beijing Solarbio Science & Technology
Co., Ltd., Beijing, China) in strict accordance with the manufacturer's instructions. RNA concentration was determined using a spectrometer. The primers were synthesized by Takara Biotechnology Co., Ltd.
(Dalian, Liaoning, China; 
| Western blot analysis
After the total protein had been extracted from both TC and adjacent normal tissues, the protein concentration of each sample was determined using a bicinchoninic acid ( final concentration: 100 U/mL). Following incubation at 37°C with 5% CO 2 , RT-qPCR was performed in an attempt to select the cell line with the highest expression levels of lncRNA TNRC6C-AS1. Cells at the logarithmic growth stage were selected for subsequent experimentation.
| Cell grouping and transfection
Thyroid carcinoma SW579 cells displaying logarithmic growth were seeded into a 6-well plate. When cell confluence reached 80%-90%, lncRNA RP11-468E2.5 shRNA (Santa Cruz Biotechnology, Dallas, TX, USA) sequences and X-tremeGENE shRNA transfection agent were diluted using 50 μL of 1640 medium and fully mixed together.
After incubation for 20 minute, the mixture was added into a 6-well plate. Following transfection, the plate was incubated under satu- order to confirm successful transfection. 19 A transfection efficiency of >75% was considered to be reflective of successful transfection.
| Fluorescence in situ hybridization
The localization of TNRC6C-AS1 expression in SW579 cells was predicted using the website http://lncatlas.crg.eu/. TNRC6C-AS1 sub-cellular localization was detected using a fluorescence in situ hybridization (FISH) kit (Roche, Basel, Switzerland). Fluorescence images were obtained under a confocal laser scanning microscope (FV1000; Olympus, Tokyo, Japan). Each experiment was repeated three times.
| Luciferase reporter gene assay
The 
| RNA-binding protein immunoprecipitation
The RT-qPCR using TNRC6C-AS1-specific primers as depicted in Table 1 .
| Chromatin immunoprecipitation
The enrichment analysis of DNMT1, DNMT2 and DNMT3 in STK4 promoter region was conducted using a chromatin immunoprecipitation (CHIP) kit (Millipore). The binding of DNMT1, DNMT2 and DNMT3 to STK4 promoter region was detected using specific primers in STK4
promoter region (Table 1) . Each experiment was repeated three times.
| Immunofluorescence staining
Following conventional detachment and transfection, the cells were 
| 3-(4,5)-dimethylthiahiazo (-z-y1)-3,5-diphenytetrazoliumromide assay
When cell density had reached approximately 80% following transfection, the SW579 cells were washed twice with PBS, detached with 0.25% trypsin, and a single cell suspension was then prepared. After tallying, the cells were seeded into a 96-well plate at a cell density 
| 5-Ethynyl-2'-deoxyuridine assay
Thyroid carcinoma cells at the logarithmic growth phase were seeded into a 96-well plate with 2 × 10 3 to 4 × 10 4 cells in each well, which were then permitted to attach over a 24 hour period. Transfection was performed with triplicate wells in each group. Next, 100 μL fixative was added into each well and incubated for 30 minute at room temperature. Next, 2 mg/mL glycine was added into each well for another 5 minute of incubation. The plate was then washed with PBS (100 μL/well) for 5 minute. A penetrant (100 μL/well, PBS containing 0.5% Triton X-100) was subsequently added and incubated for 
| Flow cytometry
| Hoechst staining
A coverslip was placed on the 6-well plate. 
| Monodansylcadaverine staining
An autophagy inhibitor, 3-MA, was diluted using sterile PBS culmi- 
| Observation under a transmission electron microscope
After the cells had been collected, they were then fixed in a 2.5%
glutaraldehyde solution at 4°C overnight and washed four times with 0.1 mol/L PBS. After aspirating the PBS, the cells were fixed with osmic acid at 4°C for 1 hour, dehydrated with gradient acetone (50%, 70%, 90% and 100%) and subsequently dried. The embedded cells were then polymerized in an oven prior to the preparation of electron microscopic serial sections. During transmission electron microscope (TEM) analysis, the slices were placed on a single-sample rod in . Panel E, RT-qPCR was used to determine the relative expression of TNRC6C-AS1 and STK4 after the transfection. Panel F, G, Western blot analysis was used to determine the relative protein expression of STK4 after the transfection. *P < 0.05 vs. the OE-TNRC6C-NC and si-TNRC6C-NC groups; the data are expressed as mean ± standard deviation and analysed using t test and one-way ANOVA; the experiment was repeated three times 
| Statistical analysis
| RE SULTS
| LncRNA TNRC6C-AS1 was highly expressed while STK4 was reduced in TC tissues
Initially, based on the analysis results of The Cancer Genome Atlas (TCGA), TNRC6C-AS1 was determined to be highly expressed in TC tissues while STK4 was poorly expressed. As depicted in Figure 1A , A negative correlation was found between TNRC6C-AS1 and STK4. RT-qPCR and Western blot analysis methods were performed in order to determine the expression levels of lncRNA TNRC6C-AS1 and STK4 in TC and adjacent normal tissues. The results revealed notably elevated lncRNA TNRC6C-AS1 expressions while the levels of STK4 were decreased in TC tissues when compared the adjacent normal tissues (P < 0.05; Figure 1B-D) . Next, an immunohistochemistry assay was performed in order to detect the STK4-positive expression, the results of which indicated that the positive expression of STK4 was primarily in the cytoplasm, while the positive rate of STK4 was much lower in the TC tissues when compared to the adjacent normal tissues (P < 0.05; Figure 1E ,F).
RT-qPCR methods were further conducted in an attempt to select the TC cell line with the highest TNRC6C-AS1 expression.
Compared with normal thyroid cell line Nthy-ori 3-1, the relative expression of TNRC6C-AS1 elevated in TC cell lines FRO, ARO, PDTC-1 and SW579, among which the cell line SW579 exhibited the highest TNRC6C-AS1 expression (P < 0.05; Figure 1G ). On the basis of the aforementioned findings, the TC cell line SW579 was selected for subsequent experiments.
| STK4 was a downstream target gene of TNRC6C-AS1
The sub-cellular localization of TNRC6C-AS1 was predicted using the site http://lncatlas.crg.eu/, which revealed that TNRC6C-AS1 was located in the nucleus of multiple cell lines (Figure 2A ). This finding was further verified by experimental FISH means, which demonstrated that TNRC6C-AS1 was primarily expressed in the nucleus ( Figure 2B ).
Furthermore, we used an online bioinformatics analysis software Blast and luciferase assays to examine whether TNRC6C-AS1 was markedly down-regulated in the OE-TNRC6C group (P < 0.05).
Compared with the si-TNRC6C-NC group, the opposite tendency was observed in the si-TNRC6C group (P < 0.05). All the obtained data indicated that STK4 expression could be regulated by TNRC6C-AS1.
| TNRC6C-AS1 inhibited STK4 expression through DNA methylation
MethPrimer software was applied for the analysis of CpG island in STK4 promoter region by inputting nucleotide sequence around 3000 bp close to the STK4 promoter region. The results revealed that STK4 promoter region was located in the CpG island ( Figure 3A) , indicating that STK4 expression was indeed affected by promoter methylation. In order to verify as to whether TNRC6C-AS1 was associated with the methylation level of STK4 promoter region, 78 cases of TC samples were randomly selected with the methylation level of the CpG island in the STK4 promoter region of the selected samples were detected using methylation-specific polymerase (MSP). The results revealed that the methylation level of STK4 was notably elevated in the TC tissues compared to that of the adjacent normal tissues (P < 0.05; Figure 3B ). The obtained results suggested that the STK4 expression decreased as the methylation level increased, which provided evidence proving that STK4 was poorly expressed in TC tissues ( Table 2) 
| STK4 modulated the Hippo signalling pathway
The effects of STK4 on the Hippo signalling pathway were investigated through the application of a Western blot analysis ( Figure 4A,B) .
The results revealed that compared with the NC group, the OE-STK4 group exhibited elevated levels of MST1, LAST1 and LAST2, as well as increased YAP1 phosphorylation (P < 0.05). An opposite trend was observed in the si-STK4 group (P < 0.05). STK4, serine/threonine-protein kinase 4. *P < 0.05 vs. adjacent normal tissue; measurement data are analysed by t test; N = 78; the experiment was repeated three times.
TA B L E 2 Methylation level of STK4 in thyroid carcinoma and adjacent normal tissues
Immunofluorescence staining was performed in order to detect the nuclear transfer of YAP1 in SW579 cells. As illustrated in with the si-NC group, the si-STK4 group exhibited much higher OD values at 48 and 72 hour, with a greater presence of red-stained apoptotic cells (P < 0.05). Flow cytometry and Hoechst staining were employed to detect cell apoptosis. As shown in Figure 5G -J, the apoptotic rate in the OE-STK4 group was higher than that in the NC group (P < 0.05), while the OE-STK4 group exhibited more distinct pyknotic, broken and white nuclei. A reduced apoptotic rate was found in the si-STK4 group, which was accompanied by a reduced number of pyknotic, broken and white nuclei (P < 0.05). Furthermore, cell autophagy was assessed using MDC fluorescent staining and TEM. The results ( Figure 5K-N 
| D ISCUSS I ON
According to the Cancer Statistics in China, 2015, TC continues to exhibit a substantial upward trend among the female population, particularly those under the age of 30 years old. 20 Despite the relatively low mortality rate and excellent prognosis, symptoms in 21 Accumulating evidence has demonstrated the potential role of lncRNAs in TC progression and development. For example, the lncRNA PVT1 has been reported to contribute to the tumorigenesis of TC. 22 In the present study, we investigated the role of the particular long non-coding RNA TNRC6C-AS1 in TC. Our results demonstrated that the silencing of lncRNA TNRC6C-AS1 could suppress TC cell proliferation and tumorigenesis while promoting apoptosis and autophagy through the inhibition of STK4 methylation via the Hippo signalling pathway.
A key initial observation of our study revealed that STK4 was a downstream target gene of lncRNA TNRC6C-AS1. However, lncRNA TNRC6C-AS1 could be enriched by DNMT1, DNMT2 and DNMT3 and might regulate STK4 methylation level through binding to CpG island of STK4 promoter. DNA methylation has been defined as an epigenetic mechanism of gene regulation with reports suggesting it may be associated with mammalian development and disease. 23 A previously conducted functional study asserted that the methylation in CpG island of promoters results in silencing of its downstream genes at a transcriptional level, or the inactivation of tumour suppressor genes in specific cancers. 24 As a maintenance methyltransferase, DNMT1 is of great significance from a cell survival and tumorigenesis perspective, particularly in the cytosine hypermethylation in CpG islands of tumour suppressor genes. 25 In addition, reports have suggested that when STK3/4 is inactivated, YAP can translocate to the nucleus and increase the gene expression of its target, which off course was consistent with our results whereby YAP1 translocation from the cytoplasm to the nucleus was enhanced in the si-STK4 group. 26 The Hippo signalling pathway has been speculated to result in the phosphorylation of TAZ (transcriptional co-activator with PDZ-binding motif), a co-activator of YAP/transcription. Thus, their respective translocation to the nucleus could be prevented when gene activation is avoided and cell apoptosis is inhibited. 27 Our study also demonstrated that silencing of lncRNA TNRC6C-AS1 or the up-regulation of STK4 could inhibit proliferation and Researchers have demonstrated that STK4 knockout mice exhibit enhanced levels of apoptosis, although STK4 deficiency in humans may elevate the degree of susceptibility to recurrent infections. 26 More importantly, the loss of STK3/STK4 has been documented to lead to autophagic structure accumulation and increased LC3II expression, which may further affect cells' ability to fight against infection. 28 Evidence has been presented suggesting that the LC3 family plays a role in the biogenesis and completion of autophagosomes. 26 The Hippo signalling pathway plays a crucial role in tissue growth through its downstream effector, YAP1. 29 Inactivated YAP1
has been speculated to function as a therapeutic target, owing to its ability to reduce tumour volume while inhibiting invasion and metastasis in mice with TC. 30 Likewise, similar experimental data obtained in a prior study published by Liu et al 27 revealed that the expression levels of autophagy markers, including Beclin-1, LC3I
and LC3II, were reduced in thyroid papillary carcinoma cells.
| CON CLUS ION
In conclusion, the key findings presented in our study suggest that the over-expression of lncRNA TNRC6C-AS1 is associated with the development of TC through the modulation of cell apoptosis and autophagy by promoting STK4 methylation via inhibition of the Hippo signalling pathway (Figure 7 ). Specific methylation in cancer cells has been highlighted as a biomarker owing to its high sensitivity to aberrant methylation in cancer. 24 This being said, our study potentially provides a theoretical basis for which lncRNA TNRC6C-AS1 may be premised upon as a therapeutic target for TC treatment. However, due to the limited sample size and experimental conditions of this study, further studies are required in order to further our understanding in relation to the role of lncRNA TNRC6C-AS1 in TC. 
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